Propulsion of Peripheral Neuropathic Pain Clinical Trial Pipeline as Novel and Extensive 10+ Therapies Likely to Enter in the Domain | DelveInsight

(Albany, United States) As per DelveInsight's assessment, globally, the Peripheral Neuropathic Pain Pipeline constitutes 10+ key companies continuously working towards developing 10+ Peripheral Neuropathic Pain Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

In the Peripheral Neuropathic Pain pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Peripheral Neuropathic Pain NDA approvals (if any), and product development activities comprising the technology, Peripheral Neuropathic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

To explore more information on the latest breakthroughs in the Peripheral Neuropathic Pain Pipeline treatment landscape of the report, click here @ Peripheral Neuropathic Pain Pipeline Outlook- https://www.delveinsight.com/report-store/peripheral-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Peripheral Neuropathic Pain Pipeline Report
• DelveInsight's Peripheral Neuropathic Pain Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading companies working in the Peripheral Neuropathic Pain Market include Haisco Pharmaceutical Group, AlzeCure, Eli Lilly and Company, Bayer, Eliem Therapeutics, SIMR Biotech, Aptinyx, Lexicon Pharmaceuticals, and others.
• Promising Peripheral Neuropathic Pain pipeline therapies in the various stages of development include Duloxetine, Pregabalin, DS-5565, RGH-896, Pregabalin, and others.
• On March 2023, AlzeCure Pharma announced a study of phase 2 clinical trials for ACD440 Gel 14mg/g. This is a double-blind, randomized, placebo-controlled crossover outpatient study in patients with peripheral neuropathic pain with allodynia or hyperalgesia to cold, heat, brush and/ or pinprick stimulation. Patients will in random order receive ACD440 Gel or placebo treatment twice daily for 7 days, topically applied to the painful area. This is followed by a 2-week washout period, then receive the alternate treatment.
• On May 2023, Eliem Therapeutics (UK) Ltd announced a study of phase 2 clinical trials for ETX-018810. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects with Diabetic Peripheral Neuropathic Pain.

Peripheral Neuropathic Pain Overview
Neuropathic pain is defined by the International Association for the Study of Pain as pain caused by a lesion or disease of the somatosensory nervous system. Neuropathic pain (NP) is not a particular disease, but the clinical condition that is caused by a variety of different diseases and lesions, injuring the nervous system at peripheral or central level, resulting in peripheral NP or central NP, respectively.

For further information, refer to the detailed Peripheral Neuropathic Pain Unmet Needs, click here for Peripheral Neuropathic Pain Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral Neuropathic Pain Emerging Drugs Profile
• HSK 16149: Haisco Pharmaceutical Group
• ACD 440: AlzeCure

Peripheral Neuropathic Pain Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Peripheral Neuropathic Pain. The companies which have their Peripheral Neuropathic Pain drug candidates in the most advanced stage, i.e. phase II/III include, Haisco Pharmaceutical Group.

Request a sample and discover the recent advances in Peripheral Neuropathic Pain Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Peripheral Neuropathic Pain Segmentation- https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral Neuropathic Pain Drugs and Companies
• Duloxetine: Eli Lilly and Company
• Pregabalin: Shionogi
• DS-5565: Daiichi Sankyo Co. Ltd.

Peripheral Neuropathic Pain Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Peripheral Neuropathic Pain Therapeutics Market include-
Haisco Pharmaceutical Group, AlzeCure, Eli Lilly and Company, Bayer, Eliem Therapeutics, SIMR Biotech, Aptinyx, Lexicon Pharmaceuticals, and others.

Dive deep into rich insights for drugs for Peripheral Neuropathic Pain Pipeline, click here @ Peripheral Neuropathic Pain Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Peripheral Neuropathic Pain Pipeline Report
• Coverage- Global
• Companies- Haisco Pharmaceutical Group, AlzeCure, Eli Lilly and Company, Bayer, Eliem Therapeutics, SIMR Biotech, Aptinyx, Lexicon Pharmaceuticals, and others.
• Therapies- Duloxetine, Pregabalin, DS-5565, RGH-896, Pregabalin, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Peripheral Neuropathic Pain Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Peripheral Neuropathic Pain: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Peripheral Neuropathic Pain- DelveInsight's Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Drug Name: Company Name
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase II/ III)
11. HSK 16149: Haisco Pharmaceutical Group
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. ACD 440: AlzeCure
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Peripheral Neuropathic Pain Key Companies
21. Peripheral Neuropathic Pain Key Products
22. Peripheral Neuropathic Pain - Unmet Needs
23. Peripheral Neuropathic Pain - Market Drivers and Barriers
24. Peripheral Neuropathic Pain - Future Perspectives and Conclusion
25. Peripheral Neuropathic Pain Analyst Views
26. Peripheral Neuropathic Pain Key Companies
27. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.